Lineage Cell Therapeutics Inc (AMEX:LCTX)
$ 0.6126 0.0052 (0.86%) Market Cap: 133.88 Mil Enterprise Value: 103.92 Mil PE Ratio: 0 PB Ratio: 1.74 GF Score: 61/100

Lineage Cell Therapeutics Inc Corporate Analyst Meeting Transcript

Feb 22, 2021 / 09:30PM GMT
Release Date Price: $2.76 (-1.08%)
Jason Wesly McCarthy
Maxim Group LLC, Research Division - Senior MD

Good afternoon, everyone. My name is Jason McCarthy. I am the Head of Biotechnology Equity Research with Maxim Group. And it is with great pleasure to welcome you to today's virtual event, featuring Lineage Cell Therapeutics and an in-depth discussion on the company's allogeneic cell therapy program, OPC1, for treating spinal cord injury.

As a research analyst, as many of my colleagues in the business would tell you, there are any number of therapeutic categories to cover, each with exciting companies and science and medicine that could be and often is transformative. And you could look at oncology, inflammatory disease, gene therapy, NASH. And what about Alzheimer's disease? It's been a pretty hot-button topic just in the last couple of weeks alone.

And these are just a handful of spaces, and all are different. But what links them is that each has had its areas of tremendous success. And with it sometimes comes parabolic-like rises in valuations. So my question is what about cell therapy?

Sure, we can always

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot